Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan, a generic pharmaceutical company, has announced that its India-based subsidiary Matrix Laboratories, has received the first and only World Health Organization approval for lopinavir/ritonavir tablets, 200mg/50mg.
Subscribe to our email newsletter
Matrix’s version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates.
Lopinavir/ritonavir tablets are the generic version of Abbott Laboratories’s Kaletra tablets, the brand marketed in the US and Europe, and alluvia tablets, the brand marketed in the developing world. It is used in combination with other medications to control HIV infection and is included in the antiretroviral (ARV) class of drugs known as HIV protease inhibitors.
Robert Coury, vice chairman and CEO of Mylan, said: “Mylan and Matrix are committed to our growing and high quality ARV franchise. Our goal is to provide HIV treatments to patients around the world – especially in developing countries. With Matrix’s heat-stable and affordable version of lopinavir/ritonavir, patients in remote parts of developing nations now have access to this important medicine.”